Tage Thorstensen
Forsker
Forfattere
Raghuram Badmi Torstein Tengs May Bente Brurberg Abdelhameed Elameen Yupeng Zhang Lisa Karine Haugland Carl Gunnar Fossdal Timo Hytönen Paal Krokene Tage ThorstensenSammendrag
Grey mold caused by the necrotrophic fungal pathogen Botrytis cinerea can affect leaves, flowers, and berries of strawberry, causing severe pre- and postharvest damage. The defense elicitor β-aminobutyric acid (BABA) is reported to induce resistance against B. cinerea and many other pathogens in several crop plants. Surprisingly, BABA soil drench of woodland strawberry (Fragaria vesca) plants two days before B. cinerea inoculation caused increased infection in leaf tissues, suggesting that BABA induce systemic susceptibility in F. vesca. To understand the molecular mechanisms involved in B. cinerea susceptibility in leaves of F. vesca plants soil drenched with BABA, we used RNA sequencing to characterize the transcriptional reprogramming 24 h post-inoculation. The number of differentially expressed genes (DEGs) in infected vs. uninfected leaf tissue in BABA-treated plants was 5205 (2237 upregulated and 2968 downregulated). Upregulated genes were involved in pathogen recognition, defense response signaling, and biosynthesis of secondary metabolites (terpenoid and phenylpropanoid pathways), while downregulated genes were involved in photosynthesis and response to auxin. In control plants not treated with BABA, we found a total of 5300 DEGs (2461 upregulated and 2839 downregulated) after infection. Most of these corresponded to those in infected leaves of BABA-treated plants but a small subset of DEGs, including genes involved in ‘response to biologic stimulus‘, ‘photosynthesis‘ and ‘chlorophyll biosynthesis and metabolism’, differed significantly between treatments and could play a role in the induced susceptibility of BABA-treated plants.
Forfattere
Johanna Eva Bodin Tage Thorstensen Muath K Alsheikh Dean Basic Rolf Brudvik Edvardsen Knut Tomas Dalen Nur Duale Ole Martin Eklo Åshild Gunilla Ergon Anne-Marthe Ganes Jevnaker Kjetil Hindar Leiv Sigve Håvarstein Martin Malmstrøm Kaare Magne Nielsen Siri Lie Olsen Eli Knispel Rueness Monica Sanden Ville Erling Sipinen Kristine von Krogh Dag Inge Våge Anna Wargelius Per Hans Micael Wendell Siamak Pour Yazdankhah Jan Alexander Ellen Merete Bruzell Gro Ingunn Hemre Vigdis Vandvik Angelika Agdestein Edel O. Elvevoll Dag Olav Hessen Merete Hofshagen Trine Husøy Helle Katrine Knutsen Åshild Krogdahl Asbjørn Magne Nilsen Trond Rafoss Olaug Taran Skjerdal Inger-Lise Karin Steffensen Tor Arne Strand Gaute Velle Yngvild WastesonSammendrag
The Norwegian Scientific Committee for Food and Environment (VKM) initiated this work to examine the extent to which organisms developed by genome-editing technologies pose new challenges in terms of risk assessment. This report considers whether the risk assessment guidance on genetically modified organisms, developed by the European Food Safety Authority (EFSA), can be applied to evaluate potential risks of organisms developed by genome editing. Background Gene technology has allowed for the transfer of genes between organisms and species, and thereby to design altered genotypes with novel traits, i.e. GMOs. A new paradigm started in the early 2000s with the development of genome-editing techniques. Unlike traditional genetic modification techniques resulting in insertion of foreign DNA fragments at random locations in the genome, the new genome-editing techniques additionally open for a few single nucleotide edits or short insertions/deletions at a targeted site in an organism’s genome. These new techniques can be applied to most types of organisms, including plants, animals and microorganisms of commercial interest. An important question is how the novel, genome-edited organisms should be evaluated with respect to risks to health and the environment. The European Court of Justice decided in 2018 to include genome-edited organisms in the GMO definition and hence in the regulatory system already in place. This implies that all products developed by genome-editing techniques must be risk-assessed within the existing regulatory framework for GMOs. The European and Norwegian regulatory frameworks regulate the production, import and placing on the market of food and feed containing, consisting of or produced from GMOs, as well as the release of GMOs into the environment. The assessment draws on guidance documents originally developed by EFSA for risk assessment of GMOs, which were drawn up mainly to address risks regarding insertion of transgenes. The new genome-editing techniques, however, provide a new continuum of organisms ranging from those only containing a minor genetic alteration to organisms containing insertion or deletion of larger genomic regions. Risk assessment of organisms developed by genome editing The present discourse on how new genome-editing techniques should be regulated lacks an analysis of whether risk assessment methodologies for GMOs are adequate for risk assessment of organisms developed through the use of the new genome-editing techniques. Therefore, this report describes the use of genome-editing techniques in food and feed production and discusses challenges in risk assessment with the regulatory framework. Specifically, this report poses the question as to whether the EFSA guidance documents are sufficient for evaluating risks to health and environment posed by genome-edited plants, animals and microorganisms. To address these questions, the report makes use of case examples relevant for Norway. These examples, intended for food and feed, include oilseed rape with a modified fatty acid profile, herbicide-tolerant and pest-resistant crops, sterile salmon, virus-resistant pigs and hornless cattle. The report considers all aspects of the stepwise approach as described in the EFSA guidance documents. Conclusions The inherent flexibility of the EFSA guidance makes it suitable to cover health and environmental risk assessments of a wide range of organisms with various traits and intended uses. Combined with the embedded case-by-case approach the guidance is applicable to genome-edited organisms. The evaluation of the guidance demonstrates that the parts of the health and environmental risk assessment concerned with novel traits (i.e. the phenotype of the organism) may be fully applied to all categories of genome-edited organisms. ............
Forfattere
Monica Sanden Johanna Eva Bodin Nur Duale Kristian Prydz Volha Shapaval Anne-Marthe Ganes Jevnaker Ville Erling Sipinen Tage ThorstensenSammendrag
The Norwegian Scientific Committee for Food and Environment (VKM) has assessed an application for approval of the genetically modified maize DP23211 for food and feed uses, import and processing in the EU. In accordance with an assignment specified by the Norwegian Food Safety Authority (NFSA) and the Norwegian Environment Agency (NEA), VKM assesses whether genetically modified organisms (GMOs) intended for the European market can pose risks to human or animal health, or the environment in Norway. VKM assesses the scientific documentation regarding GMO applications seeking approval for use of GMOs as food and feed, processing, or cultivation. The EU Regulation 1829/2003/EC (Regulation) covers living GMOs that fall under the Norwegian Gene Technology Act, as well as processed food and feed from GMOs (dead material) that fall under the Norwegian Food Act. The regulation is currently not part of the EEA agreement or implemented in Norwegian law. Norway conducts its own assessments of GMO applications in preparation for the possible implementation of the Regulation. In accordance with the assignment by NFSA and NEA, VKM assesses GMO applications during scientific hearings initiated by the European Food Safety Authority (EFSA), as well as after EFSA has published its own risk assessment of a GMO, up until EU member countries vote for or against approval in the EU Commission. The assignment is divided into three stages. (link) Maize DP23211 DP23211 is a genetically modified maize that expresses the double-stranded ribonucleic acid (dsRNA) DvSSJ1, and the insecticidal protein IPD072Aa, both conferring resistance to corn rootworm pests. DP23211 maize also expresses the enzyme phosphinothricin acetyltransferase (PAT) for tolerance to glufosinate herbicide, and the enzyme phosphomannose isomerase (PMI) used as a selectable marker during development. The scientific documentation provided in the application for DP23211 maize is adequate for risk assessment, and in accordance with EFSA guidance on risk assessment of genetically modified plants for use in food or feed. The VKM GMO panel does not consider the introduced modifications in DP23211 maize to imply potential specific health or environmental risks in Norway, compared to EU-countries. The EFSA scientific Opinion is adequate also for Norwegian conditions. Therefore, a full risk assessment of DP23211 maize was not performed by the VKM GMO Panel. About the assignment: In stage 1, VKM shall assess the health and environmental risks of the genetically modified organism and derived products in connection with the EFSA scientific hearing of GMO applications. VKM shall review the scientific documentation that the applicant has submitted and possibly provide comments to EFSA. VKM must also consider: i) whether there are specific Norwegian conditions that could give other risks in Norway than those mentioned in the application, ii) whether the Norwegian diet presents a different health risk for the Norwegian population should the GMO be approved, compared to the European population, and iii) risks associated with co-existence with conventional and/or ecologic production of plants for GMOs seeking approval for cultivation. Relevant measures to ensure co-existence must also be considered. In stage 2, VKM shall assess whether comments from Norway have been satisfactorily answered by EFSA. In addition, VKM shall assess whether comments from other countries imply need for further follow-up. If EFSAs response to Norwegian comments is not satisfactory, or comments by other countries imply the need for further follow-up, VKM shall in stage 3 perform a risk assessment of these conditions, including conditions specific to Norway.
Forfattere
Monica Sanden Johanna Eva Bodin Nur Duale Anne-Marthe Ganes Jevnaker Kristian Prydz Volha Shapaval Ville Erling Sipinen Tage ThorstensenSammendrag
Det er ikke registrert sammendrag
Forfattere
Monica Sanden Eirill Ager-Wick Johanna Eva Bodin Nur Duale Anne-Marthe Ganes Jevnaker Kristian Prydz Ville Erling Sipinen Volha Shapaval Tage ThorstensenSammendrag
Vitenskapskomiteen for mat og miljø (VKM) har vurdert en søknad om godkjenning av den genmodifiserte maisen MON 95275. Maisen er søkt godkjent til import, videreforedling og til bruk som mat og fôr i EU-området. I et løpende oppdrag fra Mattilsynet og Miljødirektoratet, vurderer VKM om genmodifiserte organismer og prosessert mat og fôr fra disse kan utgjøre en risiko for helse og miljø. EUs forordning 1829/2003/EF (Forordningen) omfatter både genmodifiserte organismer (levende), som faller inn under den norske genteknologiloven, og genmodifisert, prosessert mat og fôr (dødt materiale avledet fra GMO) som faller inn under den norske matloven. Forordningen er i dag ikke en del av EØS-avtalen eller norsk rett. Norge vurderer søknadene som en forberedelse til at forordningen eventuelt implementeres. VKM vurderer søknader både i den vitenskapelige høringsperioden, som den europeiske myndighet for næringsmiddeltrygghet (EFSA) gjennomfører, og i perioden fra EFSA har offentliggjort en risikovurdering og til EUs medlemsland stemmer for eller imot godkjenning av den genmodifiserte organismen i kommisjonen. VKMs oppdraget er delt inn i tre trinn. (lenke oppdragsbrev) Mais MON 95275 MON 95275 er en genmodifisert mais utviklet ved transformasjon av planteceller ved hjelp av Agrobacterium tumefaciens. MON 95275 uttrykker transgenene mpp75Aa1.1 og vpb4Da2, som henholdsvis koder for proteinene Mpp75Aa1.1 (Cry) og Vpb4Da2 (Vip), og et dobbelt-trådet RNA transkript DvSnf7. Transgenene gjør MON 95275 resistent mot enkelte planteskadegjørere i insektordenen Coleoptera (biller). Den vitenskapelige dokumentasjonen i søknaden for mais MON 95275 er dekkende for risikovurdering, og i samsvar med EFSAs retningslinjer for risikovurdering av genmodifiserte planter til bruk i mat eller fôr. De genetiske endringene i mais MON 95275 tilsier ingen økt helse- eller miljørisiko i Norge sammenlignet med EU-land. EFSAs risikovurdering er dermed tilstrekkelig også for norske forhold. Ettersom det ikke har blitt identifisert særnorske forhold vedrørende mais MON 95275, har VKMs GMO panel ikke utført en fullstendig risikovurdering. Om oppdraget: I trinn 1 skal VKM, i forbindelse med EFSAs vitenskapelige høring av GMO-søknader, vurdere helse- og miljørisiko ved den genmodifiserte organismen og dens avledete produkter. VKM skal gjennomgå den vitenskapelige dokumentasjonen som søker har sendt inn og evt. gi innspill til EFSA. VKM skal også vurdere: i) om det er særnorske forhold som vil kunne gi andre risikoer i Norge enn de som er omtalt i søknaden, ii) om norsk kosthold kan gi en økt helserisiko for befolkningen i Norge ved en eventuell godkjenning, sammenliknet med befolkningen i resten av Europa, og iii) risiko knyttet til sameksistens med konvensjonell og/eller økologisk produksjon for genmodifiserte planter som søkes godkjent for dyrking. Aktuelle virkemidler for å sikre sameksistens skal også vurderes. I trinn 2 skal VKM vurdere om innspill fra Norge er tilfredsstillende besvart av EFSA. I tillegg skal VKM vurdere om noen av EFSAs kommentarer til andre lands innspill gir grunnlag for videre oppfølging. Dersom EFSAs svar til norske innspill ikke er tilfredsstillende, eller andre lands innspill gir grunnlag for videre oppfølging, skal VKM i trinn 3 utføre en risikovurdering av de aktuelle forholdene, inkludert eventuelle særnorske forhold.
